Evotec SE (EVO) Liabilities and Shareholders Equity (2009 - 2026)
Evotec SE (EVO) posted Liabilities and Shareholders Equity of $1.9 million for Q1 2026, up 96125.58% sequentially from $1995.1 in Q4 2025, and down 6.16% YoY from $2.0 million in Q1 2025.
Evotec SE (EVO) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends
Evotec SE has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $1.9 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 6.16% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (down 100.0% YoY) and the FY2025 annual result came in at $1995.1, down 100.0% from the prior year.
- Liabilities and Shareholders Equity rose to $1.9 million in Q1 2026 per EVO's latest filing, from $1995.1 in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $2399.4 billion in Q1 2024 and troughed at $1995.1 in Q4 2025.
- A 5-year average of $382.3 billion and a median of $2.4 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity surged 4610.0% in 2024, then tumbled 100.0% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $55.0 million in 2022, then decreased by 21.06% to $43.4 million in 2023, then soared by 4610.0% to $2.0 billion in 2024, then sank by 100.0% to $1995.1 in 2025, then jumped by 96125.58% to $1.9 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.9 million, $1995.1, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 6.18 Bn |
| 10 | Evotec SE | 687.23 Mn | 686.75 Mn | - | 1.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.92 Mn |
| Dec 31, 2025 | 1,995.11 |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | 2.05 Mn |
| Dec 31, 2024 | 2.04 Bn |
| Sep 30, 2024 | 2,186.35 Bn |
| Mar 31, 2024 | 2,399.39 Bn |
| Dec 31, 2023 | 43.39 Mn |
| Dec 31, 2022 | 54.97 Mn |
| Sep 30, 2022 | 2.28 Mn |
| Mar 31, 2022 | 2.45 Mn |
| Dec 31, 2021 | 29.12 Mn |
| Sep 30, 2021 | 2.08 Mn |
| Dec 31, 2020 | 23.00 Mn |
| Dec 31, 2019 | 12.69 Mn |
| Sep 30, 2010 | 230,107.36 |
| Jun 30, 2010 | 192,993.83 |
| Mar 31, 2010 | 200.13 Mn |
| Dec 31, 2009 | 216,487.76 |